Faculty Opinions recommendation of Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Keyword(s):
Phase 2
◽
2015 ◽
Vol 93
(4)
◽
pp. 757-764
◽